Nourish raises $100M Series C at $1.75B valuation to scale AI-powered nutrition care
What's the deal? Nourish, a New York-based virtual nutrition startup founded in 2021, has raised $100M in a Series C round led by Menlo Ventures, valuing the company at $1.75B. Thrive Capital, Index Ventures, J.P. Morgan Growth Equity PartnersDealroom has a profile for this one. Try Dealroom →, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners also participated. Total funding now stands at $215M.
The company operates the US's largest dietitian-led metabolic health clinic, with more than 10,000 registered dietitians — up from 3,000 in early 2025. It pairs them with AI health agents to deliver virtual, insurance-covered nutrition care. Menlo Ventures partner Jean-Paul Sanday joins the board.
Why now? The explosion of GLP-1 weight-loss drugs like Ozempic and Wegovy has created a care gap. Fewer than half of patients stay on GLP-1s past six months, and most who stop regain weight without sustained nutrition support.
Payers are under growing pressure to find scalable solutions that bend the cost curve. Nourish claims its model delivers over $2,000 in annual savings per patient, with clinical outcomes including 8% weight loss, 1.3-point A1C reductions, and significant cholesterol and blood pressure improvements. The startup says it is profitable and has tripled revenue over the past year.
What could go wrong? Nourish's model depends on insurance reimbursement and payer partnerships. Any shift in coverage policies — particularly around GLP-1 medications or telehealth — could disrupt growth. Competition is heating up: rival Fay NutritionDealroom has a profile for this one. Try Dealroom → secured funding from Goldman SachsDealroom has a profile for this one. Try Dealroom → at a $500M valuation last year, while established players like WeightWatchersDealroom has a profile for this one. Try Dealroom → and Noom have struggled to adapt to the GLP-1 era.
Some Nourish patients have turned to copycat GLP-1 offerings, which have drawn regulatory scrutiny — prompting the company to begin prescribing GLP-1s in-house earlier this year.
The signal: This round reflects a broader bet that GLP-1s will reshape healthcare, not replace it. Investors are backing the idea that medication alone won't solve chronic disease — and that the real value lies in wrapping lifestyle and behaviour change around pharmaceuticals. Nearly 200M Americans live with nutrition-related chronic conditions, driving close to $5T in annual healthcare spending. With coverage for more than 200M lives through payer partnerships, Nourish is positioning itself as essential infrastructure for the post-GLP-1 care model.
Read more: Nourish · Bloomberg · Business Wire · Business of Fashion · Pulse 2.0 · Morningstar
Image credit: Nourish
J.V.
